Breaking News Instant updates and real-time market news.

ABBV

AbbVie

09:31
11/28/16
11/28
09:31
11/28/16
09:31

AbbVie downgraded to Neutral from Buy at Citi

  • 03

    Dec

  • 05

    Dec

ABBV AbbVie

11/01/16
WBLR
11/01/16
DOWNGRADE
Target $81
WBLR
Market Perform
William Blair downgrades Vertex with competition looming
William Blair analyst Y. Katherine Xu downgraded Vertex Pharmaceuticals (VRTX) to Market Perform from Outperform after attending the North American Cystic Fibrosis Conference. Looming competition "has become more and more real," Xu tells investors in a research note. The triple combo in vitro data from Vertex, AbbVie (ABBV)/Galapagos (GLPG) and Proteostasis (PTI) appear comparable, Xu contends. The analyst expects "deteriorating pricing" for the Vertex's Cystic Fibrosis franchise starting in 2022 due to competition. She lowered her price target for the shares to $81 from $105. Vertex closed yesterday at $78.86.
11/07/16
SBSH
11/07/16
NO CHANGE
Target $36
SBSH
Buy
Citi says buy Coherus Biosciences on today's selloff
Citi analyst Mohit Bansal recommends using today's selloff in shares of Coherus Biosciences (CHRS) as a buying opportunity. Checks with patent experts indicate that the patent in today's case is not a key obstacle against a biosimilar of AbbVie's Humira, Bansal tells investors in a research note. Further, the analyst estimates fair value of Coherus shares at $24 if the Humira biosimilar is removed completely. The stock is currently down 16%, or $4.60, to $23.55. Basel does not expect a biosimilar launch until 2020. He adds that every one year launch delay post 2020 would impact his fair value for shares by only $1. The analyst keeps a Buy rating on Coherus with a $36 price target.
11/07/16
COWN
11/07/16
NO CHANGE
Target $45
COWN
Outperform
Coherus has other paths to pursue in AbbVie patent fight, says Cowen
Cowen analyst Ken Cacciatore noted the U.S. Patent Trial and Appeals Board decided to deny institution of Coherus Biosciences' (CHRS) Inter Partes Review against AbbVie's (ABBV) '166 patent related to Humira, though he believes that Coherus still has other remaining pathways in its patent fight over the drug. "Today's news, although a setback, should be treated as a relatively minor" one, he tells investors. Cacciatore has an Outperform rating and $45 price target on Coherus shares.
11/08/16
BARD
11/08/16
NO CHANGE
Target $40
BARD
Outperform
Coherus Biosciences weakness a buying opportunity, says Baird
Baird analyst Michael Ulz noted Coherus (CHRS) received a decision denying the institution of the '166 IPR related to Abbie's (ABBV) Humira. Though the decision was disappointing, the analyst sees multiple opportunities remaining to circumvent the patent. Ulz said he would be a buyer on the weakness in Coherus and reiterated his Outperform rating and $40 price target on the shares.

TODAY'S FREE FLY STORIES

LEJU

Leju

$2.46

0.07 (2.93%)

20:05
06/22/17
06/22
20:05
06/22/17
20:05
Downgrade
Leju rating change  »

Leju downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GCP

GCP Applied Technologies

$30.40

0.3 (1.00%)

20:04
06/22/17
06/22
20:04
06/22/17
20:04
Upgrade
GCP Applied Technologies rating change  »

GCP Applied Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHM

PulteGroup

$24.04

-0.24 (-0.99%)

19:58
06/22/17
06/22
19:58
06/22/17
19:58
Initiation
PulteGroup initiated  »

PulteGroup initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$33.47

-0.5 (-1.47%)

19:58
06/22/17
06/22
19:58
06/22/17
19:58
Initiation
D.R. Horton initiated  »

D.R. Horton initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAA

CalAtlantic

$34.80

-0.34 (-0.97%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
CalAtlantic initiated  »

CalAtlantic initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZH

Beazer Homes

$13.01

0.03 (0.23%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Beazer Homes initiated  »

Beazer Homes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTH

Meritage Homes

$40.40

-0.4 (-0.98%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Meritage Homes initiated  »

Meritage Homes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Toll Brothers initiated  »

Toll Brothers initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$52.41

-0.84 (-1.58%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Lennar initiated  »

Lennar initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$22.23

-0.1 (-0.45%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
KB Home initiated  »

KB Home initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

MHK

Mohawk

$242.70

-0.22 (-0.09%)

19:27
06/22/17
06/22
19:27
06/22/17
19:27
Initiation
Mohawk initiated  »

Mohawk initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBHS

Fortune Brands

$65.09

0.06 (0.09%)

19:27
06/22/17
06/22
19:27
06/22/17
19:27
Initiation
Fortune Brands initiated  »

Fortune Brands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

JELD-WEN Holding

$34.60

-0.29 (-0.83%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
JELD-WEN Holding initiated  »

JELD-WEN Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBP

Installed Building Products

$52.75

-1 (-1.86%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Installed Building Products initiated  »

Installed Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OC

Owens Corning

$66.42

-0.85 (-1.26%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Owens Corning initiated  »

Owens Corning initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHR

Whirlpool

$195.16

1.35 (0.70%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Whirlpool initiated  »

Whirlpool initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$38.82

0.06 (0.15%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Masco initiated  »

Masco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEG

Leggett & Platt

$52.66

-0.16 (-0.30%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Leggett & Platt initiated  »

Leggett & Platt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USG

USG

$29.29

0.35 (1.21%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
USG initiated  »

USG initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSTE

Caesarstone

$35.20

1.05 (3.07%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Caesarstone initiated  »

Caesarstone initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

, GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

19:18
06/22/17
06/22
19:18
06/22/17
19:18
Hot Stocks
YouTube says reaches 1.5B monthly users »

In a blog post Thursday,…

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

AHH

Armada Hoffler

$13.70

-0.07 (-0.51%)

19:08
06/22/17
06/22
19:08
06/22/17
19:08
Downgrade
Armada Hoffler rating change  »

Armada Hoffler downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

SBUX

Starbucks

$59.51

-0.45 (-0.75%)

18:59
06/22/17
06/22
18:59
06/22/17
18:59
Initiation
Starbucks initiated  »

Starbucks initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

GPMT

Granite Point Mortgage

18:16
06/22/17
06/22
18:16
06/22/17
18:16
Syndicate
Granite Point Mortgage 10M share IPO priced at $19.50 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

TWO

Two Harbors

$10.39

0.02 (0.19%)

, GPMT

Granite Point Mortgage

18:15
06/22/17
06/22
18:15
06/22/17
18:15
Hot Stocks
Two Harbors to contribute commercial real estate assets to Granite Point »

Two Harbors Investment…

TWO

Two Harbors

$10.39

0.02 (0.19%)

GPMT

Granite Point Mortgage

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.